These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21840662

  • 1. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
    Fox D, O'Connor R, Mallon P, McMahon G.
    J Pharm Biomed Anal; 2011 Dec 05; 56(4):785-91. PubMed ID: 21840662
    [Abstract] [Full Text] [Related]

  • 2. Rifampicin determination in plasma by stir bar-sorptive extraction and liquid chromatography.
    Balbão MS, Bertucci C, Bergamaschi MM, Queiroz RH, Malfará WR, Dreossi SA, de Paula Mello L, Queiroz ME.
    J Pharm Biomed Anal; 2010 Apr 06; 51(5):1078-83. PubMed ID: 20005065
    [Abstract] [Full Text] [Related]

  • 3. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G, Khoo S, Jack C, Lalloo U.
    J Antimicrob Chemother; 2006 Dec 06; 58(6):1299-302. PubMed ID: 17032686
    [Abstract] [Full Text] [Related]

  • 4. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.
    Clin Pharmacol Ther; 2011 Sep 06; 90(3):406-13. PubMed ID: 21814190
    [Abstract] [Full Text] [Related]

  • 5. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring.
    Allanson AL, Cotton MM, Tettey JN, Boyter AC.
    J Pharm Biomed Anal; 2007 Aug 15; 44(4):963-9. PubMed ID: 17531423
    [Abstract] [Full Text] [Related]

  • 6. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK, Nanzigu S, Waako P, Ogwal-Okeng J, Gustafson LL, Aklillu E.
    Pharmacogenomics; 2014 Aug 15; 15(11):1423-35. PubMed ID: 25303294
    [Abstract] [Full Text] [Related]

  • 7. Simple and rapid liquid chromatography method for determination of efavirenz in plasma.
    Ramachandran G, Kumar AK, Swaminathan S, Venkatesan P, Kumaraswami V, Greenblatt DJ.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May 01; 835(1-2):131-5. PubMed ID: 16574512
    [Abstract] [Full Text] [Related]

  • 8. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N, Purwantyastuti, Instiaty, Rusli A.
    Acta Med Indones; 2016 Jan 01; 48(1):10-6. PubMed ID: 27241539
    [Abstract] [Full Text] [Related]

  • 9. Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.
    Cabrera SE, Cordero M, Iglesias A, Valverde MP, Domínguez-Gil A, García MJ.
    AIDS; 2008 Nov 30; 22(18):2549-51. PubMed ID: 19005282
    [No Abstract] [Full Text] [Related]

  • 10. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM.
    J Acquir Immune Defic Syndr; 2009 Apr 15; 50(5):439-43. PubMed ID: 19223781
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous determination of rifampicin and efavirenz in plasma.
    Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ.
    Ther Drug Monit; 2002 Oct 15; 24(5):670-4. PubMed ID: 12352941
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
    Notari S, Bocedi A, Ippolito G, Narciso P, Pucillo LP, Tossini G, Donnorso RP, Gasparrini F, Ascenzi P.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb 02; 831(1-2):258-66. PubMed ID: 16406832
    [Abstract] [Full Text] [Related]

  • 13. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin.
    Hartkoorn RC, Khoo S, Back DJ, Tjia JF, Waitt CJ, Chaponda M, Davies G, Ardrey A, Ashleigh S, Ward SA.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep 15; 857(1):76-82. PubMed ID: 17643357
    [Abstract] [Full Text] [Related]

  • 14. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K.
    AIDS; 2005 Sep 23; 19(14):1481-6. PubMed ID: 16135901
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J.
    Clin Pharmacokinet; 2002 Sep 23; 41(9):681-90. PubMed ID: 12126459
    [Abstract] [Full Text] [Related]

  • 16. [Validation of a liquid chromatography method for rifampicin determination in human plasma].
    Moreno-Exebio L, Grande-Ortiz M.
    Rev Peru Med Exp Salud Publica; 2014 Sep 23; 31(1):56-61. PubMed ID: 24718527
    [Abstract] [Full Text] [Related]

  • 17. A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector.
    Yin K, Meng X, Dong P, Ding T, Shen L, Zhang L, Zhang R, Cai W, Lu H.
    Biosci Trends; 2014 Aug 23; 8(4):227-34. PubMed ID: 25224629
    [Abstract] [Full Text] [Related]

  • 18. A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments.
    Bienvenu E, Hoffmann KJ, Ashton M, Kayumba PC.
    Biomed Chromatogr; 2013 Nov 23; 27(11):1554-9. PubMed ID: 23780715
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K, N2R Study Team.
    Clin Infect Dis; 2009 Jun 15; 48(12):1752-9. PubMed ID: 19438397
    [Abstract] [Full Text] [Related]

  • 20. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.
    J Antimicrob Chemother; 2017 May 01; 72(5):1441-1449. PubMed ID: 28175315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.